You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company was founded by Washington State University scientists to offer molecular breeding and genomic services for cannabis cultivation.
The San Diego-based DNA synthesis firm this week announced $12.2 million in Series A funding, but has plans to expand the round.
The company plans to use the funding to finish developing and commercially launch its HD-Mapping whole-genome electronic mapping platform.
The firm will use the funding to advance its enzymatic DNA synthesis technology, which has applications in life sciences, information storage, synthetic biology, and electronics.
The Swiss company markets the WAVE system, a waveguide interferometry-based instrument for studying molecular interactions in real time.
The Seattle startup is looking to partner with pharmaceutical companies and offer its yeast fusion sequencing technology as a contracted research service.
The company said the money from the transactions will help it boost adoption of its ConfirmMDx and SelectMDx prostate cancer tests with urologists and payors.
The Boston-based synthetic biology firm said it will use the funds to grow its cell programing platform, which it will make available to startups.
The company, founded in May 2018 and headquartered in Guangzhou in southern China, has developed a CRISPR-based rapid diagnostics platform for pathogen detection.
The synthetic biology and DNA data storage firm will use the funds to launch its BioXp 3200 automated gene synthesis and cloning platform.
Following discrimination allegations, NICHD's Constantine Stratakis withdraws from a new position at the Research Institute of the McGill University Health Center, Science reports.
US President Donald Trump has threatened to cut World Health Organization funding over its pandemic response, which would affect its ability to do its work and which he might not be able to do.
The US Securities and Exchange Commission has halted the sales of a handful of stocks over claims made about the coronavirus.
In Nature this week: comparative analyses of single-cell RNA sequencing protocols uncover differences between approaches, and more.